Form 4: Accuray Director Steven Mayer Granted 45,620 Restricted Stock Units

Accuray Inc. Director Steven F. Mayer was granted 45,620 Restricted Stock Units, aligning his interests with shareholders through future vesting.

Summary

• Steven F. Mayer, a Director of Accuray Inc. (ARAY), was granted 45,620 Restricted Stock Units (RSUs) on June 30, 2025.
• Each RSU represents a contingent right to receive one share of Accuray's common stock.
• The granted RSUs will vest 100% on November 21, 2025.
• Following this transaction, Steven F. Mayer beneficially owns 45,620 derivative securities (RSUs) and 45,620 underlying common shares.

Sentiment

Score: 6

Explanation: The document reports a routine equity grant to a director, which is a positive for corporate governance and alignment of interests, but it does not contain information that would significantly alter the company's financial outlook or operational performance.

Positives

• The grant of Restricted Stock Units to a director aligns management and board interests with those of shareholders, as the value of the compensation is tied to the company's stock performance.
• The specified vesting schedule encourages long-term commitment from the director.

Negatives

• No negative information is disclosed in this Form 4 filing.

Risks

• No specific risks are mentioned in this Form 4 filing.

Future Outlook

The document indicates a future vesting event for the granted Restricted Stock Units on November 21, 2025, which will result in the conversion of these units into common stock.

Industry Context

The granting of Restricted Stock Units to directors is a common practice across various industries, including the medical technology sector where Accuray operates, serving as a standard form of equity compensation to attract and retain talent and align their interests with long-term company performance.

Comparison to Industry Standards

• The use of Restricted Stock Units (RSUs) as a form of director compensation is a widely accepted practice across publicly traded companies, including those in the medical device and healthcare technology sectors.
• While specific grant sizes vary based on company size, director responsibilities, and compensation philosophy, a grant of 45,620 RSUs for a director at a company like Accuray (ARAY) is generally within the typical range for non-employee director equity compensation, aiming to align their interests with shareholder value creation.
• The vesting schedule, with a 100% vest on a future date (November 21, 2025), is also a standard approach for director equity grants, promoting retention and long-term focus.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director helps align the director's financial interests with those of shareholders, potentially encouraging decisions that enhance long-term shareholder value.

Next Steps

• The 45,620 Restricted Stock Units are scheduled to vest 100% on November 21, 2025, at which point they will convert into shares of Accuray Inc. common stock.

Key Dates

Keywords

Accuray Inc., ARAY, Steven F. Mayer, Restricted Stock Units, RSU, insider transaction, director compensation, SEC Form 4, equity grant